✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Saxenda

Released: Last reviewed:

Brand name for liraglutide 3.0 mg daily, FDA-approved for chronic weight management.

By Novo Nordisk
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Saxenda overview

Brand name for liraglutide 3.0 mg daily, FDA-approved for chronic weight management.

Saxenda at a glance

Manufacturer
Novo Nordisk
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

The Saxenda label (effective February 25, 2026) covers weight management in adults and in patients 12 and older weighing more than 60 kg with obesity, as a once-daily injection alongside diet and activity. In the liraglutide adolescent trial (NEJM 2020), BMI fell 4.64 percentage points more with liraglutide than with placebo over 56 weeks, and rose again after the drug was stopped. FDA drug-shortage data (openFDA) list liraglutide injection as in shortage. Medicare’s GLP-1 Bridge covers Foundayo, Wegovy and the Zepbound KwikPen, not Saxenda.